Potential Role of Donor-derived Cell-Free DNA as a Biomarker in Cardiac Allograft Vasculopathy
NCT ID: NCT04791852
Last Updated: 2021-09-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
94 participants
OBSERVATIONAL
2019-01-10
2021-04-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Stem Cell Migratory Activity: Prognostic Marker in Myocardial Ischemia
NCT01271309
Markers and Response to Cardiac Resynchronization Therapy
NCT01519908
Observational Study on Cardiac Biomarkers Testing in Patients with Muscular Dystrophy Cardiomyopathy
NCT05779202
Assessment of Translesional Markers and Metabolomics
NCT00321139
Ruling Out Coronary Artery Disease and Myocardial Injury by Biomarkers
NCT04144725
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Donor-derived Cell Free DNA
We will compare ddcfDNA with coronary angiogram determined CAV grading, according to ISHTL2010 classification
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Multiorgan transplant
* History of acute cellular rejection ≥ 1R or antibody mediated rejection in the previous 6 months
* Concomitant infection by CMV
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Puerta de Hierro University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Javier Segovia Cubero
Head of Cardiology Department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Puerta de Hierro
Majadahonda, Madrid, Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Jimenez-Blanco Bravo M, Perez-Gomez L, Hernandez-Perez FJ, Arellano-Serrano C, Torres-Sanabria M, Gomez-Bueno M, Oteo-Dominguez JF, Mingo-Santos S, Segovia-Cubero J. Lack of Usefulness of Donor-Derived Cell-Free DNA as a Biomarker for Cardiac Allograft Vasculopathy: A Prospective Study. Front Cardiovasc Med. 2022 Apr 6;9:856600. doi: 10.3389/fcvm.2022.856600. eCollection 2022.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FreeDNA-CAV
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.